

11-29-05

1614  
CASE ON/4-32752A JFW



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 48366878545  
Express Mail Label Number

November 28, 2005  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF  
JOHN ARTHUR HOHNEKER  
INTERNATIONAL APPLICATION NO: PCT/EP03/12593  
FILED: 11 NOVEMBER 2003  
U.S. APPLICATION NO: 10/534,572 ✓  
35 USC §371 DATE: 11 MAY 2005  
FOR: TREATMENT OF MESOTHELIOMA

**MS: Amendment**  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:


Applicant believes this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The asterisked references were cited in the International Search Report and since copies of said references were forwarded by the International Bureau, only copies of the non-asterisked references are enclosed.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

A handwritten signature in cursive script, reading "Lydia T. McNally", written over a horizontal line.


Lydia T. McNally  
Attorney for Applicant  
Reg. No. 36,214

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7898

Date: *November 22, 2005*

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)



ATTY. DOCKET NO.  
ON/4-32752A  
APPLICATION NO.  
10/534,572  
APPLICANT  
John Arthur Hohneker  
FILING DATE  
MAY 11, 2005

Group

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	*WO 01/10859	02/15/01	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Ascoli, Scalzo, Facciolo and Nardi, "Platelet-Derived Growth Factor Receptor Immunoreactivity in Mesothelioma and Nonneoplastic Mesothelial Cells in Serous Effusions", <i>Acta Cytologica</i> , Vol. 39, No. 4, pp. 613-622 (1995).
AS	Fitzpatrick, Peroni and Bielefeldt-Ohmann, "The Role of Growth Factors and Cytokines in the Tumorigenesis and Immunobiology of Malignant Mesothelioma", <i>Am J Respir Cell Mol</i> , Vol. 12, No. 5, pp. 455-460 (1995).
AT	Garlepp and Leong, "Biological and Immunological Aspects of Malignant Mesothelioma", <i>Eur Respir J</i> , Vol. 8, No. 4, pp. 643-650 (1995).

**EXAMINER**

**DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.  
ON/4-32752A  
APPLICATION NO.  
10/534,572  
APPLICANT  
John Arthur Hohneker  
FILING DATE  
MAY 11, 2005

Group

EXAMINER  
INITIAL

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

DA	Klominek, Baskin and Hauzenberger, "Platelet-Derived Growth Factor (PDGF) BB Acts as a Chemoattractant for Human Malignant Mesothelioma Cells via PDGF Receptor $\beta$ - Integrin $\alpha\beta 1$ Interaction", <i>Clin Exp Metastasis</i> , Vol. 16, No. 6, pp. 529-539 (1998).
DB	Langerak et al., "Expression of the Wilms' Tumor Gene <i>WT1</i> in Human Malignant Mesothelioma Cell Lines and Relationship to Platelet-Derived Growth Factor A and Insulin-Like Growth Factor 2 Expression", <i>Genes Chromosomes Cancer</i> , Vol. 12, No. 2, pp. 87-96 (1995).
DC	Langerak, van der Linden-van Beurden and Versnel, "Regulation of Differential Expression of Platelet-Derived Growth Factor $\alpha$ - and $\beta$ -Receptor mRNA in Normal and Malignant Human Mesothelial Cell Lines", <i>Biochim Biophys Acta</i> , Vol. 1305, Nos. 1-2, pp. 63-70 (1996).
DD	Langerak et al., "Expression of Platelet-Derived Growth Factor (PDGF) and PDGF Receptors in Human Malignant Mesothelioma <i>in Vitro</i> and <i>in Vivo</i> ", <i>J Pathol</i> , Vol. 178, No. 2, pp. 151-160 (1996).
DE	*Lin et al., "The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK787/ZK222584 Inhibits Growth and Migration of Multiple Myeloma Cells in the Bone Marrow Microenvironment", <i>Cancer Res</i> , Vol. 62, No. 17, pp. 5019-5026 (2002).
DF	*Maung, "Novel Drugs in Development for Malignant Mesothelioma", <i>Clin Lung Cancer</i> , Vol. 4, No. 3, pp. 146-148 (2002).
DG	Metheny-Barlow et al., "Paradoxical Effects of Platelet-Derived Growth Factor-A Overexpression in Malignant Mesothelioma. Antiproliferative Effects <i>In Vitro</i> and Tumorigenic Stimulation <i>In Vivo</i> ", <i>Am J Respir Cell Mol Biol</i> , Vol. 24, No. 6, pp. 694-702 (2001).
DH	Pogrebniak, Lubensky and Pass, "Differential Expression of Platelet Derived Growth Factor- $\beta$ in Malignant Mesothelioma: A Clue to Future Therapies?", <i>Surg Oncol</i> , Vol. 2, No. 4, pp. 235-240 (1993).
DI	Ruffié, "New Therapeutic Options for Mesothelioma", <i>Rev Pneumol Clin</i> , Vol. 58, No. 5, Pt. 2, pp.3S15-3S18 (2002) – English Translation.
DJ	Syrokou, Tzanakakis, Hjerpe and Karamanos, "Proteoglycans in Human Malignant Mesothelioma. Stimulation of their Synthesis Induced by Epidermal, Insulin and Platelet-Derived Growth Factors Involves Receptors with Tyrosine Kinase Activity", <i>Biochimie</i> , Vol. 81, No. 7, pp. 733-744 (1999).
DK	Van der Meeren et al., "Tumorigenic Conversion of Human Mesothelial Cells as a Consequence of Platelet-Derived Growth Factor-A Chain Overexpression", <i>Am J Respir Cell Mol Biol</i> , Vol. 8, No. 2, pp. 214-221 (1993).
DL	Versnel et al., "Human Malignant Mesothelioma Cell Lines Express PDGF $\beta$ -Receptors Whereas Cultured Normal Mesothelial Cells Express Predominantly PDGF $\alpha$ -Receptors", <i>Oncogene</i> , Vol. 6, No. 11, pp. 2005-2011 (1991).
DM	Zanella, Posada, Tritton and Mossman, "Asbestos Causes Stimulation of the Extracellular Signal-Regulated Kinase 1 Mitogen-Activated Protein Kinase Cascade after Phosphorylation of the Epidermal Growth Factor Receptor", <i>Cancer Res</i> , Vol. 56, No. 23, pp. 5334-5338 (1996).
DN	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.